M&G Plc grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 59.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 154,717 shares of the biopharmaceutical company’s stock after purchasing an additional 57,709 shares during the quarter. M&G Plc’s holdings in Gilead Sciences were worth $10,675,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in GILD. International Assets Investment Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $1,649,000. Cerity Partners LLC lifted its stake in shares of Gilead Sciences by 102.4% in the 4th quarter. Cerity Partners LLC now owns 146,740 shares of the biopharmaceutical company’s stock valued at $11,888,000 after purchasing an additional 74,249 shares during the period. Sapient Capital LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $324,000. Valeo Financial Advisors LLC lifted its stake in shares of Gilead Sciences by 7.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 7,363 shares of the biopharmaceutical company’s stock valued at $596,000 after purchasing an additional 491 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Gilead Sciences during the 4th quarter worth $49,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
Gilead Sciences Stock Performance
Shares of Gilead Sciences stock opened at $73.98 on Wednesday. The firm has a market cap of $92.17 billion, a price-to-earnings ratio of 205.50, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. The stock’s 50-day moving average is $70.20 and its 200-day moving average is $70.30. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.
Gilead Sciences Announces Dividend
Analyst Ratings Changes
Several analysts recently commented on the company. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research note on Wednesday, April 24th. Royal Bank of Canada raised their price objective on Gilead Sciences from $71.00 to $72.00 and gave the stock a “sector perform” rating in a research note on Friday, August 9th. TD Cowen dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, UBS Group dropped their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $81.88.
Read Our Latest Stock Report on GILD
Insider Activity at Gilead Sciences
In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
- Five stocks we like better than Gilead Sciences
- Most active stocks: Dollar volume vs share volume
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- Upcoming IPO Stock Lockup Period, Explained
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- Pros And Cons Of Monthly Dividend Stocks
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.